Allergic conjunctivitis future or investigational therapies: Difference between revisions
Jump to navigation
Jump to search
| Line 7: | Line 7: | ||
* [[Topical]] <ref name="pmid22378107">{{cite journal| author=Tzu JH, Utine CA, Stern ME, Akpek EK| title=Topical calcineurin inhibitors in the treatment of steroid-dependent atopic keratoconjunctivitis. | journal=Cornea | year= 2012 | volume= 31 | issue= 6 | pages= 649-54 | pmid=22378107 | doi=10.1097/ICO.0b013e31822481c2 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22378107 }} </ref> and [[systemic]] [[cyclosporine]] a (CsA) <ref name="pmid20491051">{{cite journal| author=Cornish KS, Gregory ME, Ramaesh K| title=Systemic cyclosporin A in severe atopic keratoconjunctivitis. | journal=Eur J Ophthalmol | year= 2010 | volume= 20 | issue= 5 | pages= 844-51 | pmid=20491051 | doi=10.1177/112067211002000506 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20491051 }} </ref> have been suggested in the treatment of severe [[atopic]] [[keratoconjunctivitis]]. | * [[Topical]] <ref name="pmid22378107">{{cite journal| author=Tzu JH, Utine CA, Stern ME, Akpek EK| title=Topical calcineurin inhibitors in the treatment of steroid-dependent atopic keratoconjunctivitis. | journal=Cornea | year= 2012 | volume= 31 | issue= 6 | pages= 649-54 | pmid=22378107 | doi=10.1097/ICO.0b013e31822481c2 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22378107 }} </ref> and [[systemic]] [[cyclosporine]] a (CsA) <ref name="pmid20491051">{{cite journal| author=Cornish KS, Gregory ME, Ramaesh K| title=Systemic cyclosporin A in severe atopic keratoconjunctivitis. | journal=Eur J Ophthalmol | year= 2010 | volume= 20 | issue= 5 | pages= 844-51 | pmid=20491051 | doi=10.1177/112067211002000506 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20491051 }} </ref> have been suggested in the treatment of severe [[atopic]] [[keratoconjunctivitis]]. | ||
* Use of [[CsA]] appears to be safe and can eliminate the need/dependence of [[steroids]]. | * Use of [[CsA]] appears to be safe and can eliminate the need/dependence of [[steroids]]. | ||
* Others [[calcineurin]] inhibitors that appears to be well tolerated by patients with severe [[atopic]] [[blepharoconjunctivitis]]<ref name="pmid16965503">{{cite journal| author=Virtanen HM, Reitamo S, Kari M, Kari O| title=Effect of 0.03% tacrolimus ointment on conjunctival cytology in patients with severe atopic blepharoconjunctivitis: a retrospective study. | journal=Acta Ophthalmol Scand | year= 2006 | volume= 84 | issue= 5 | pages= 693-5 | pmid=16965503 | doi=10.1111/j.1600-0420.2006.00699.x | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16965503 }} </ref> and severe [[atopic]] [[keratoconjunctivitis] | * Others [[calcineurin]] inhibitors that appears to be well tolerated by patients with severe [[atopic]] [[blepharoconjunctivitis]]<ref name="pmid16965503">{{cite journal| author=Virtanen HM, Reitamo S, Kari M, Kari O| title=Effect of 0.03% tacrolimus ointment on conjunctival cytology in patients with severe atopic blepharoconjunctivitis: a retrospective study. | journal=Acta Ophthalmol Scand | year= 2006 | volume= 84 | issue= 5 | pages= 693-5 | pmid=16965503 | doi=10.1111/j.1600-0420.2006.00699.x | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16965503 }} </ref> and severe [[atopic]] [[keratoconjunctivitis]] are [[tacrolimus]] and [[pimecrolimus]]<ref name="pmid12464150">{{cite journal| author=Reynolds NJ, Al-Daraji WI| title=Calcineurin inhibitors and sirolimus: mechanisms of action and applications in dermatology. | journal=Clin Exp Dermatol | year= 2002 | volume= 27 | issue= 7 | pages= 555-61 | pmid=12464150 | doi=10.1046/j.1365-2230.2002.01148.x | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12464150 }} </ref>. | ||
===Mapracorat<ref name="pmid22194647">{{cite journal| author=Baiula M, Spartà A, Bedini A, Carbonari G, Bucolo C, Ward KW | display-authors=etal| title=Eosinophil as a cellular target of the ocular anti-allergic action of mapracorat, a novel selective glucocorticoid receptor agonist. | journal=Mol Vis | year= 2011 | volume= 17 | issue= | pages= 3208-23 | pmid=22194647 | doi= | pmc=3244483 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22194647 }} </ref>=== | |||
==References== | ==References== | ||
Revision as of 09:13, 30 August 2022
|
Allergic conjunctivitis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Allergic conjunctivitis future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of Allergic conjunctivitis future or investigational therapies |
|
FDA on Allergic conjunctivitis future or investigational therapies |
|
CDC on Allergic conjunctivitis future or investigational therapies |
|
Allergic conjunctivitis future or investigational therapies in the news |
|
Blogs on Allergic conjunctivitis future or investigational therapies |
|
Risk calculators and risk factors for Allergic conjunctivitis future or investigational therapies |
Overview
Future or Investigational therapies
Calcineurin inhibitors
- They are capable of inducing local immunosuppression by blocking Th2 lymphocyte proliferation and IL-2 production and reducing eosinophils via inhibition of IL-5.
- Topical [1] and systemic cyclosporine a (CsA) [2] have been suggested in the treatment of severe atopic keratoconjunctivitis.
- Use of CsA appears to be safe and can eliminate the need/dependence of steroids.
- Others calcineurin inhibitors that appears to be well tolerated by patients with severe atopic blepharoconjunctivitis[3] and severe atopic keratoconjunctivitis are tacrolimus and pimecrolimus[4].
Mapracorat[5]
References
- ↑ Tzu JH, Utine CA, Stern ME, Akpek EK (2012). "Topical calcineurin inhibitors in the treatment of steroid-dependent atopic keratoconjunctivitis". Cornea. 31 (6): 649–54. doi:10.1097/ICO.0b013e31822481c2. PMID 22378107.
- ↑ Cornish KS, Gregory ME, Ramaesh K (2010). "Systemic cyclosporin A in severe atopic keratoconjunctivitis". Eur J Ophthalmol. 20 (5): 844–51. doi:10.1177/112067211002000506. PMID 20491051.
- ↑ Virtanen HM, Reitamo S, Kari M, Kari O (2006). "Effect of 0.03% tacrolimus ointment on conjunctival cytology in patients with severe atopic blepharoconjunctivitis: a retrospective study". Acta Ophthalmol Scand. 84 (5): 693–5. doi:10.1111/j.1600-0420.2006.00699.x. PMID 16965503.
- ↑ Reynolds NJ, Al-Daraji WI (2002). "Calcineurin inhibitors and sirolimus: mechanisms of action and applications in dermatology". Clin Exp Dermatol. 27 (7): 555–61. doi:10.1046/j.1365-2230.2002.01148.x. PMID 12464150.
- ↑ Baiula M, Spartà A, Bedini A, Carbonari G, Bucolo C, Ward KW; et al. (2011). "Eosinophil as a cellular target of the ocular anti-allergic action of mapracorat, a novel selective glucocorticoid receptor agonist". Mol Vis. 17: 3208–23. PMC 3244483. PMID 22194647.